Tarvos Capital

Tavros Therapeutics is a precision oncology platform company that leverages next-generation functional and computational genomics to discover novel drug targets. The company's proprietary platform identifies synthetic lethal relationships, uncovering unique vulnerabilities within tumors to develop first-in-class small-molecule therapies. Founded in 2019 and headquartered in Durham, North Carolina, Tavros has entered into significant strategic collaborations with Zentalis Pharmaceuticals and Vividion Therapeutics. In January 2025, the company was acquired by Vividion Therapeutics, a subsidiary of Bayer, to enhance its chemoproteomics-led drug discovery efforts. Tavros continues to focus on addressing high unmet needs in oncology by targeting previously 'undruggable' cancer-causing proteins.